Portable microwave tech used in treating skin lesions
9 November 2018, by Roddy Isles

Scottish company Emblation is at the forefront of new technology in the dermatology market with a highly effective treatment for plantar warts. The device has been used in more than 15,000 wart treatments UK wide to date and works by coagulating soft tissue, and inducing a local immune response.

Charlotte Proby, Professor of Dermatology at the University of Dundee, is leading the research study to examine the effectiveness of the treatment against AK.

Professor Proby said, "This technology appears to have significant potential to offer efficient treatment of actinic keratosis, a common condition which affects many among our older population.

"Removing these lesions can offer protection against more serious skin diseases including some forms of cancer, and an effective treatment that can be delivered quickly and at low cost would be a significant development.

"The results and experimental data will provide a starting point for a Randomised Control Trial (RCT) after the project. An RCT is high risk and cost without this project."

The technology will be tested for use on AK in conjunction with the Tayside Clinical Trials Unit (TCTU) who will run the trial at the Division of Cancer Research at the University of Dundee. The study is being funded by Innovate UK.

Dr. Matt Kidd, R&D Director at Emblation, said, "The enrolment of the first patients in this seminal study for the treatment of Actinic Keratosis is a significant milestone for Emblation's platform technology.

"We have been working closely with our partners from the University of Dundee for a number of months now and we're confident we will have
clinical and in-vitro data from our microwave-based platform technology to offer a disruptive, efficient treatment for AK and other lesions that would benefit from a localised immune response therapy.

"The funding from Innovate UK has been key in allowing this project to happen and helps the collaboration between Industry, Academia and the NHS – essential ingredients to medical device innovation."

Provided by University of Dundee


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.